StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

Stock analysts at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report issued on Sunday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of ADXS stock opened at $0.11 on Friday. The company has a market capitalization of $4.48 million, a P/E ratio of -0.01 and a beta of 1.81. The business’s 50 day moving average is $0.04 and its two-hundred day moving average is $0.15. Ayala Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $1.49.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.